Orchard Therapeutics Wins Swissmedic Approval for Libmeldy in Early-Onset Metachromatic Leukodystrophy (MLD)
Orchard Therapeutics (NASDAQ:ORTX), a global gene therapy leader, today announced the Swiss Agency for Therapeutic Products (Swissmedic) has approved Libmeldy® (atidarsagene autotemcel), a hematopoietic stem cell (HSC) gene therapy, for the treatment of early-onset metachromatic leukodystrophy (MLD).